Skip to main content

Discriminating the subtype of hepatic glycogen storage disease by routine blood biochemistry

In brief

Routine blood tests classified pediatric liver glycogen disease subtypes with 86.5% accuracy

In a validation group of children with genetically confirmed disease, a decision tree using triglycerides, lactate, and creatine kinase correctly classified 86.5% of hepatic glycogen storage disease subtypes. Positive predictions were especially accurate for types I and III, but the model is exploratory and needs prospective testing at multiple centers before its role in care is clear.

Journal
Pediatric investigation (Q2)
Published
18 November 2026
Study design
Prospective / inception cohort
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Xueyuan Zhang, Yuchuan Li, Weicheng Wu, Shiqi Lu, Yi Lu, Xinbao Xie, et al.
PMID
43055007
DOI
10.1002/ped4.70094

Why clinicians should know about it

  • Picked for Biochemistry (medical) (top studies of the week, 22 November 2026): Uses routine biochemistry to distinguish inherited metabolic disease subtypes

Abstract

IMPORTANCE: Early discrimination of major hepatic glycogen storage disease (GSD) subtypes is crucial for effective GSD management. OBJECTIVE: To discriminate between major hepatic GSD subtypes-types I, III, and VI/IX-using routine blood biochemical parameters. METHODS: A total of 159 pediatric patients with genetically confirmed hepatic GSD between July 2014 and July 2025 were retrospectively collected and were divided into a training set and a validation set. A random forest algorithm was first applied to identify the most predictive biochemical variables. Subsequently, a classification and regression tree model was developed based on the variables. Model performance was evaluated using overall accuracy, sensitivity, specificity, positive predictive value (PPV), and Cohen's kappa. Bootstrap resampling was used to assess model stability. RESULTS: The blood levels of triglycerides (TG), lactate (LAC), and creatine kinase (CK) were first identified as the top predictors. The resulting decision tree model classified GSD subtypes: TG ≥3.0 mmol/L and LAC ≥4.4 mmol/L for GSD I; either TG ≥3.0 mmol/L, LAC < 4.4 mmol/L, and CK ≥135.0 U/L, or TG <3.0 mmol/L, and CK ≥198.0 U/L for GSD III; TG <3.0 mmol/L and CK <198.0 U/L for GSD VI/IX. In the validation cohort, the model achieved an overall accuracy of 86.5% (kappa = 0.744), with a PPV of 91.7% for GSD I and 100% for GSD III. INTERPRETATION: This study provides an exploratory decision tree based on clinical laboratory parameters that may help discriminate among hepatic GSD subtypes, pending prospective multicenter validation.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.